Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

BACKGROUND AND OBJECTIVES: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn’s disease. While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Namour, Florence, Diderichsen, Paul Matthias, Cox, Eugène, Vayssière, Béatrice, Van der Aa, Annegret, Tasset, Chantal, Van‘t Klooster, Gerben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513223/
https://www.ncbi.nlm.nih.gov/pubmed/25681059
http://dx.doi.org/10.1007/s40262-015-0240-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513223/
https://www.ncbi.nlm.nih.gov/pubmed/25681059
http://dx.doi.org/10.1007/s40262-015-0240-z

Ejemplares similares